Real-world use of benralizumab in Chinese patients with severe eosinophilic asthma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a non-interventional, observational study collecting demographic data and patient-reported outcomes from people in China who are prescribed benralizumab for severe eosinophilic asthma. The study will track early treatment response, changes in asthma control, and treatment outcomes over time in routine clinical practice. Investigators will also record physician-reported reasons for stopping or switching benralizumab and will enroll patients who meet specified blood eosinophil thresholds. Participation requires informed consent and excludes people already treated with benralizumab, those in other clinical trials, or those with malignancy or known allergy to study medication components.

Why it matters

Who can join: the full rules

Inclusion criteria

Patients are eligible for inclusion only if all of the following criteria are met:

* Aged ≥12 years at the time of signing the informed consent form.
* Patients with severe eosinophilic asthma prescribed with benralizumab at the discretion of the clinician.
* For the patients who had received benralizumab prior to enrolment, the interval between the Index date and the date of enrolment must \<=4 weeks;
* ACQ-6 score within 7 days prior to index date is required.
* Patients must have a current prescription for benralizumab with planned initiation of therapy.
* Participating patients and/or their legally authorized representative must provide signed and dated written informed consent form prior to any study specific procedures.

Exclusion criteria

Patients should not be enrolled if any of the following exclusion criteria are met:

1. Patients currently participating in any other interventional clinical trial.
2. Known history of allergy or reaction to any component of benralizumab.
3. Malignancy of any kind.
4. Pregnant, breast-feeding or intending to become pregnant during the study period

Where it's running

• Research Site
  Anning, China Recruiting
• Research Site
  Beijing, China Recruiting
• Research Site
  Binzhou, China Recruiting
• Research Site
  Changzhou, China Recruiting
• Research Site
  Fenyang, China Recruiting
• Research Site
  Guangdong, China Recruiting

Study contacts

• Principal investigator: chen wang, PhD — China-Japan Friendship Hospital
• Study coordinator: AstraZeneca Clinical Study Information Center
• Email: information.center@astrazeneca.com
• Phone: 1-877-240-9479

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Real-world benralizumab treatment for adults with severe eosinophilic asthma in Italy

  This study will test whether benralizumab helps adults with severe eosinophilic asthma reach partial or complete clinical remission during routine care in Italy.

  Recruiting at 12 sites AstraZeneca · Salerno, Battipaglia and 27 other locations · NCT07214753

• Benralizumab in EGPA: real-world effectiveness and safety

  This is a real-world study checking how well and safely benralizumab works for adults with eosinophilic granulomatosis with polyangiitis (EGPA).

  Recruiting European EGPA Study Group · Florence, Italy · NCT07815886

• Benralizumab treatment for adults with ABPA and severe asthma

  This will test whether benralizumab helps adults (18–75) who have severe asthma with allergic bronchopulmonary aspergillosis (ABPA).

  Recruiting at 2 sites Qianfoshan Hospital · Jinan, Shandong and 1 other locations · NCT07530770

• Continued benralizumab for participants who completed a prior benralizumab study

  This trial tests continuing benralizumab in people who benefited from it in a previous study, to see if long-term treatment is safe and tolerable.

  Recruiting at 20 sites Phase 3 AstraZeneca · Aurora, Colorado and 45 other locations · NCT07444567

• Investigating benralizumab for children with eosinophilic diseases

  This study is testing if a medication called benralizumab can help children aged 6 to under 18 with eosinophilic granulomatosis with polyangiitis feel better and stay healthy over a year of treatment.

  Recruiting at 13 sites Phase 3 AstraZeneca · Aurora, Colorado and 14 other locations · NCT06512883

• Observational study on asthma control with benralizumab

  This study is testing how well benralizumab helps people with severe eosinophilic asthma manage their symptoms and improve their quality of life over a year.

  Recruiting at 40 sites AstraZeneca · Ahrensburg and 40 other locations · NCT06422078

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.